Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets 
Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Samsung Biologics and Biogen, an American biotechnology company, based in Cambridge, Massachusetts, signed a deal for the transfer of stake in Samsung Boiepis. The South Korean biotech firm headquartered in Songdo, Incheon, is buying all of Biogen’s stake in the biopharma company.
Samsung Bioepis was formed in 2012 via a joint venture between Samsung Biologics and Biogen. The latter owned a 15% stake at first, and in 2018, the percentage was increased to 50% as it extended its controlling rights in the company.
As per The Korea Herald, the acquisition of Biogen’s stake is predicted to help boost Samsung Biologic’s competitiveness in the global bio market. The value of the deal is ₩2.7 trillion or around $2.3 billion.
The total shares acquired are 10,341,852 units, and Samsung Biologics stated that the company’s board of directors approved the transaction. The payments for the stakes are set to be made in installments and will be paid over the next two years.
The full ownership of the shares will take effect once the first payment of $1 billion is completed. It was revealed that it was Biogen that forwarded a request for the buyout deal. Despite the acquisition, both companies said they would continue to work as close partners.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Biogen’s chief executive officer, Michel Vounatsos, said in a press release. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
With the transaction, Samsung Biologics Co. will take over and be in full control of Samsung Bioepis Co. since the deal is for the entire holdings of Biogen’s shares. Pulse News reported that the transfer of shares is set to take place on April 30, 2022.
Meanwhile, Samsung Bioepis is currently developing five biosimilar drugs that it will be launching worldwide. One of them is just waiting for approval and ready for marketing. The four other drugs are in the third phase of clinical trials. Two of the medicines are for oncology, and three are formulated for autoimmune.
